V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009076 | 330005870 | 1.65 | 55.75 | Adjuvant (A) | 2013-10-20 | 2013-10-24 | CVD (Neuroendocrine) | N | N | 330024316 | CARBOPLATIN + PACLITAXEL + RT |
| 330009077 | 330005872 | 1.56 | 107.15 | Palliative (P) | 2014-06-28 | 2014-06-30 | PEMBROLIZUMAB | 02 | N | 330024319 | EC |
| 330009078 | 330005873 | 1.6 | 62.2 | Palliative (P) | 2013-11-13 | 2013-11-13 | RUXOLITINIB | N | N | 330024319 | AML17 TRIAL |
| 330009079 | 330005873 | 1.8 | 8.6 | Palliative (P) | 2016-03-04 | 2016-03-11 | CHOP R - 21 days | 02 | N | 330024319 | MYELOMA XI TRIAL |
| 330009080 | 330005874 | 1.85 | null | Disease modification (D) | 2017-06-15 | 2017-07-13 | FLAG | N | N | 330024353 | IPILIMUMAB |
| 330009081 | 330005875 | 0 | 53.1 | Palliative (P) | 2017-04-23 | 2017-05-06 | AML17 TRIAL | 02 | N | 330024365 | PEMBROLIZUMAB |
| 330009082 | 330005876 | 1.78 | 91 | Palliative (P) | 2013-09-23 | 2013-12-14 | BLEOMYCIN + VINCRISTINE | N | N | 330024370 | CARBOPLATIN + VINCRISTINE |
| 330009083 | 330005877 | 0 | 88.7 | Disease modification (D) | 2016-02-15 | 2016-02-16 | MaxiCHOP (Cycle 1) | N | N | 330024378 | ADE |
| 330009084 | 330005881 | 1.61 | 77 | Palliative (P) | 2016-01-07 | 2016-01-18 | Gemcitabine day 1&8 | N | null | 330024379 | UKALL2014 |
| 330009085 | 330005881 | 1.51 | 73.7 | Neo-adjuvant (N) | null | 2016-04-21 | VIDE | N | N | 330024379 | IMATINIB |
| 330009086 | 330005884 | null | 87 | Curative (C) | 2016-07-09 | 2016-07-13 | CETUXIMAB + CISPLATIN + FU | N | N | 330024390 | CHLORAMBUCIL |
| 330009087 | 330005887 | null | 60 | Palliative (P) | null | 2014-07-04 | Cytarabine HD + Rituximab | null | N | 330024392 | UKALL 2011 |
| 330009088 | 330005888 | 0 | 84.8 | Disease modification (D) | 2015-07-18 | 2015-07-19 | AML17 TRIAL | N | N | 330024396 | BEVACIZUMAB |
| 330009089 | 330011001 | 1.79 | 90.5 | Curative (C) | 2015-10-27 | 2015-10-27 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 02 | N | 330024402 | DOXORUBICIN + HD MTX |
| 330009090 | 330011001 | 1.65 | 55.4 | Palliative (P) | null | 2015-12-29 | Topotecan (intravenous) | Y | N | 330024402 | POMALIDOMIDE |
| 330009091 | 330005889 | 1.57 | 44.6 | Curative (C) | 2015-05-25 | 2015-06-02 | ALL UKALL2011 TRIAL | 2 | N | 330024412 | UKALL2014 |
| 330009092 | 330005892 | 1.58 | 94 | Palliative (P) | 2015-10-07 | 2015-10-08 | Erlotinib | 02 | N | 330024413 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330009093 | 330005892 | null | 73.6 | null | 2015-06-13 | 2015-06-25 | MAP + MIFAMURTIDE | N | N | 330024413 | CISPLATIN + VINORELBINE |
| 330009094 | 330005892 | 1.48 | 80.5 | Palliative (P) | 2016-05-08 | 2016-06-05 | VIDE | N | N | 330024413 | EDP + MITOTANE |
| 330009095 | 330005892 | 1.5 | 111.8 | Palliative (P) | 2017-02-25 | 2017-02-25 | CAPECITABINE + CARBOPLATIN + Cetuximab | 2 | N | 330024413 | CARBOPLATIN + CETUXIMAB + FU |
| 330009096 | 330012887 | 1.82 | null | Disease modification (D) | 2013-09-11 | 2013-09-11 | CARBOPLATIN + CETUXIMAB + FU | N | null | 330024433 | CYTARABINE |
| 330009097 | 330005893 | 1.62 | 109 | Palliative (P) | 2014-06-23 | 2014-12-28 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | N | 330024452 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330009098 | 330005894 | null | 59 | Disease modification (D) | null | 2015-01-03 | Dacarbazine | null | N | 330024452 | EMA/CO |
| 330009099 | 330005894 | null | 69.2 | Neo-adjuvant (N) | 2013-12-06 | 2014-03-18 | DACTINOMYCIN | 99 | N | 330024452 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009101 | 330005896 | null | 60.98 | Adjuvant (A) | 2014-08-05 | 2014-08-09 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | N | 330024475 | EMA |
| 330009102 | 330011004 | 1.85 | 75 | Disease modification (D) | 2017-01-20 | 2017-01-20 | LEAM | N | null | 330024481 | FCR |
| 330009103 | 330011995 | 1.91 | 80 | Palliative (P) | 2016-10-03 | 2016-10-22 | Cyclophosphamide High Dose | N | N | 330024481 | VIDE |
| 330009104 | 330011995 | 1.6 | 83.2 | Palliative (P) | null | 2019-01-19 | CYCLOPHOSPHAMIDE + THALIDOMIDE | null | N | 330024481 | CAP |
| 330009106 | 330005901 | 1.58 | 80 | Palliative (P) | 2015-11-13 | 2015-11-20 | Gemcitabine day 1&8 | N | N | 330024492 | UKALL2014 |
| 330009107 | 330011997 | 1.5 | 77.2 | Curative (C) | 2017-03-25 | 2017-05-06 | Depocyte Intrathecal | null | N | 330024495 | EDP + MITOTANE |
| 330009108 | 330005904 | 1.79 | 109 | Palliative (P) | 2016-04-01 | 2016-05-05 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | 02 | N | 330024497 | EP/EMA |
| 330009109 | 330005905 | null | null | Palliative (P) | null | 2017-07-24 | AML 19 TRIAL | N | Y | 330024504 | CYTARABINE |
| 330009110 | 330005905 | null | 60 | Palliative (P) | 2013-05-15 | 2013-05-29 | DE-ESCALATE TRIAL | Y | N | 330024504 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330009111 | 330005906 | 1.69 | 69.7 | Curative (C) | 2014-12-10 | 2015-01-28 | Doxorubicin + Olaratumab | Y | N | 330024539 | OFATUMUMAB |
| 330009112 | 330005909 | 1.91 | 97.15 | Curative (C) | 2014-05-27 | 2014-05-28 | Ifosfamide | N | N | 330024541 | DHAP |
| 330009113 | 330005912 | null | 61.7 | Curative (C) | 2014-12-16 | 2015-01-16 | Cyclophosphamide+Fludara+TBI Allo | N | N | 330024541 | DOXORUBICIN + HD MTX |
| 330009114 | 330005913 | 1.55 | 57.8 | Adjuvant (A) | 2015-07-18 | 2015-07-28 | MITOTANE | 02 | N | 330024564 | MITOTANE |
| 330009115 | 330005915 | 1.62 | 75 | Palliative (P) | 2017-07-08 | 2017-07-20 | Dacarbazine | N | N | 330024564 | CAPECITABINE |
| 330009116 | 330005915 | null | 71.1 | Palliative (P) | null | 2016-03-27 | Carboplatin + Cetuximab (Cycle 1) | null | null | 330024564 | UKALL2014 |
| 330009121 | 330013096 | 1.32 | 71 | Curative (C) | 2016-04-06 | 2016-04-06 | CVD (Neuroendocrine) | 02 | N | 330024591 | BLEOMYCIN + VINCRISTINE |
| 330009122 | 330013096 | 1.78 | 52.4 | Palliative (P) | 2017-02-13 | 2017-02-13 | BUSULFAN + MELPHALAN | 2 | N | 330024591 | ETOPOSIDE + RITUXIMAB |
| 330009123 | 330013096 | 1.82 | 8.8 | Not known (9) | 2015-09-24 | 2015-11-21 | DHAP | null | null | 330024591 | BORTEZOMIB |
| 330009124 | 330013096 | 1.63 | 79.9 | Palliative (P) | 2013-12-27 | 2014-01-14 | IBRUTINIB | Y | N | 330024591 | RMS 2005 TRIAL |
| 330009125 | 330005919 | 1.82 | 82 | Adjuvant (A) | 2013-11-08 | 2013-11-24 | AML16 DA 3+8 | N | N | 330024607 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330009126 | 330011012 | 1.75 | 63 | Curative (C) | null | 2014-10-29 | VIDE | Y | null | 330024608 | VINCRISTINE |
| 330009127 | 330009227 | 0.77 | 13.5 | Palliative (P) | 2015-02-13 | 2015-02-13 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | 330024611 | FLUDARABINE |
| 330009128 | 330009227 | null | 69.1 | Disease modification (D) | 2016-04-05 | 2016-04-23 | Bortezomib +/- Dexamethasone | N | Y | 330024611 | CYTARABINE INTRATHECAL |
| 330009129 | 330005923 | 1.76 | 58 | Curative (C) | 2015-02-21 | 2015-03-27 | GC Int Guide Excranial GermCell JEB | N | N | 330024625 | CETUXIMAB + CISPLATIN + FU |
| 330009130 | 330005923 | 1.62 | null | Palliative (P) | 2014-10-10 | 2014-11-04 | IMATINIB | N | N | 330024625 | PONATINIB |
| 330009131 | 330005923 | 1.7 | 66 | Palliative (P) | 2016-04-16 | 2016-04-29 | ICE (no GCSF) | N | N | 330024625 | IFOSFAMIDE |